Of Interest

Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors

Victor Moreno, MD, PhD, medical oncologist, director, Clinical Research, START Madrid-Fundación Jimenez Diaz (FJD), discusses insights into the pharmacodynamic data for CLN-619, a novel humanized IgG1 antibody designed to bind to MICA and MICB, in patients with advanced solid tumors. Findings were presented by Moreno and colleagues during the 2024 SITC Annual Meeting.

Read More

Moffitt Study Shows Immune Structures in Melanoma Could Help Predict Patient Survival

TAMPA, Fla. — A new study has found that certain immune structures may be linked to better survival in patients with melanoma, the deadliest form of skin cancer. The study, led by researchers at Moffitt Cancer Center in collaboration with investigators at UPMC Hillman Cancer Center, was published in the Journal for ImmunoTherapy of Cancer.

Read More
MRV News
Melanoma News
Archive
Menu